Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Roche NimbleGen, Baylor College of Medicine, 454 Life Sciences, Signature Genomic Laboratories, DiaGenic, Applied Biosystems, SciGene

Illumina last week launched its Infinium High-Density HumanCytoSNP-12 DNA Analysis BeadChip.
Intended for molecular cytogeneticists, the array contains nearly 300,000 genetic markers per sample that target abnormalities found in genes and disease pathways linked to mental retardation, autism, and other anomalies.
Illumina has also released KaryoStudio, an accompanying software package. The software enables users to generate simple reports, link to cytogenetic databases, and cross-match findings against known phenotypes, the company said.

Roche NimbleGen last week launched an improved version of its Sequence Capture 385K Arrays, which are used in enriching targeted genomic regions for high-throughput sequencing.
Developed in cooperation with Baylor College of Medicine, the new arrays allow researchers to perform their own capture experiment and perform quick sequencing of enriched regions using second-generation sequencing technology such as the Genome Sequencer FLX System from fellow Roche company 454 Life Sciences, NimbleGen said.
According to NimbleGen, the entire improved sequence capture workflow now takes about two weeks. The chips are being made available as a catalog product as well as through NimbleGen’s Sequence Capture Service.

Signature Genomic Laboratories said last week that its Genoglyphix microarray visualization program is being made available to its full-service clients.
Genoglyphix allows users to visualize microarray test results for their patients over a secure online server. The program includes a genome browser that shows the syndromes and genes in the affected region, and links to the RefSeq, Online Mendelian Inheritance in Man, and PubMed databases. Through the browser, users can also access the Database of Genomic Variants to identify common copy number variants.
Previously, Genoglyphix was available only to laboratories that analyze microarray results using Signature’s research-use-only microarrays in house.

DiaGenic this week launched BCtect, a blood-based test for early detection of breast cancer. The test searches for a gene-expression signature identified by DiaGenic using a custom TaqMan array manufactured for DiaGenic by Applied Biosystems.
The TaqMan array manufactured for Oslo-based DiaGenic consists of 96 TaqMan gene expression assays pre-loaded multiple times on a 384-well microfluidic card. The array is run on ABI’s 7900HT Fast Real-time PCR System.
The test is now available in India through New Delhi-based Religare SRL. The company plans to begin selling the test in the US and in Europe next year.

SciGene this week introduced its automated system for array CGH testing in cytogenetics laboratories.
SciGene said the system improves the reliability of aCGH-based tests by automating the entire sample handling workflow from DNA to scanner by using its suite of instruments.
Specifically, the company has integrated its ArrayPrep Target Preparation System, Mai Tai Hybridization System, and Little Dipper Processor to perform all the sample processing steps from labeling to post-hybridization microarray processing to produce arrays ready for scanning.

The Scan

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.